See more : Wilmar International Limited (WLMIF) Income Statement Analysis – Financial Results
Complete financial analysis of Avalon GloboCare Corp. (AVCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avalon GloboCare Corp., a leading company in the Real Estate – Services industry within the Real Estate sector.
- Cherry AG (C3RY.DE) Income Statement Analysis – Financial Results
- dormakaba Holding AG (0QMS.L) Income Statement Analysis – Financial Results
- Bumrungrad Hospital Public Company Limited (BH.BK) Income Statement Analysis – Financial Results
- Capgemini SE (CAP.PA) Income Statement Analysis – Financial Results
- Assisted 4 Living, Inc. (ASSF) Income Statement Analysis – Financial Results
Avalon GloboCare Corp. (AVCO)
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.26M | 1.20M | 1.39M | 1.38M | 1.55M | 1.56M | 1.08M | 616.45K | 0.00 |
| Cost of Revenue | 1.02M | 929.44K | 976.45K | 987.56K | 1.21M | 1.17M | 829.79K | 73.07K | 0.00 |
| Gross Profit | 238.19K | 272.73K | 414.52K | 390.20K | 339.91K | 388.01K | 247.76K | 543.38K | 0.00 |
| Gross Profit Ratio | 18.97% | 22.69% | 29.80% | 28.32% | 21.98% | 24.84% | 22.99% | 88.15% | 0.00% |
| Research & Development | 109.62K | 731.33K | 1.03M | 883.86K | 1.78M | 39.06K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.64M | 5.66M | 8.22M | 11.96M | 16.93M | 7.68M | 2.79M | 459.55K | 31.01K |
| Selling & Marketing | 1.67M | 1.33M | 328.57K | 294.35K | 685.06K | 335.90K | 15.25K | 6.89K | 0.00 |
| SG&A | 7.31M | 6.98M | 8.22M | 11.96M | 16.93M | 8.02M | 2.80M | 466.45K | 31.01K |
| Other Expenses | 8.57M | -120.51K | 4.27K | -4.98K | 3.26K | -11.35K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.99M | 7.72M | 9.25M | 12.84M | 18.71M | 7.96M | 2.78M | 466.45K | 31.01K |
| Cost & Expenses | 17.01M | 8.65M | 10.22M | 13.83M | 19.91M | 9.13M | 3.61M | 539.51K | 31.01K |
| Interest Income | 0.00 | 3.58M | 200.48K | 168.76K | 82.91K | 4.31K | 1.37K | 575.00 | 0.00 |
| Interest Expense | 1.35M | 3.58M | 200.48K | 168.76K | 82.91K | 314.65K | 138.11K | 0.00 | 0.00 |
| Depreciation & Amortization | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26.00 | 175.51K |
| EBITDA | -15.03M | -7.89M | -8.39M | -12.08M | -16.90M | -7.16M | -3.73M | 77.53K | -31.01K |
| EBITDA Ratio | -1,196.61% | -593.84% | -607.58% | -880.57% | -1,192.42% | -454.97% | -218.21% | 12.48% | 0.00% |
| Operating Income | -15.75M | -7.44M | -8.83M | -12.45M | -18.37M | -7.63M | -3.88M | 76.93K | -31.01K |
| Operating Income Ratio | -1,254.59% | -619.12% | -635.08% | -903.93% | -1,187.81% | -488.46% | -359.88% | 12.48% | 0.00% |
| Total Other Income/Expenses | -953.33K | -3.14M | -256.67K | -225.42K | 1.31M | -421.16K | -171.78K | 575.00 | 0.00 |
| Income Before Tax | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 77.51K | -31.01K |
| Income Before Tax Ratio | -1,330.51% | -992.44% | -653.54% | -920.29% | -1,168.60% | -515.42% | -375.82% | 12.57% | 0.00% |
| Income Tax Expense | 0.00 | 749.25K | 144.29K | 112.11K | 30.39K | -278.17K | -585.36K | 21.93K | -175.50K |
| Net Income | -16.71M | -12.68M | -9.23M | -12.79M | -18.10M | -7.77M | -3.46M | 55.58K | -31.01K |
| Net Income Ratio | -1,330.51% | -1,054.77% | -663.91% | -928.43% | -1,170.57% | -497.61% | -321.50% | 9.02% | 0.00% |
| EPS | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| EPS Diluted | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| Weighted Avg Shares Out | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
| Weighted Avg Shares Out (Dil) | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
Contrasting Waste Connections (NYSE:WCN) and Avalon (NYSE:AWX)
SandRidge Permian Trust Confirms Receipt of Unsolicited Exchange Offer and Separate Sale of Assets by Sponsor
Artificial Grass Turf Market to Reach USD 1.49 Billion by 2024, Avalon BV and CoCreation Grass Corp. Emerge as Key Contributors to Growth | Technavio
'The more complaints we got, the better' – how Spitting Image redefined satire
The Latest: India's daily cases continue downward trend
The Latest: Hawaii to take over veterans home where 26 died
Financial Survey: Avalon (NYSE:AWX) vs. Advanced Disposal Services (NYSE:ADSW)
At 23.5% CAGR, Regenerative Medicine Market Size, Growth Research Analysis and Share to reach around US $19000 million by 2024
Columbia Care Reports Preliminary First Quarter 2020 Results and Provides Operational Update
Source: https://incomestatements.info
Category: Stock Reports